AI Terminal
DIACEUTICS PLC
Report Publication Announcement • Sep 8, 2022
7596_rns_2022-09-08_d4d0ee16-89a7-486f-8d1b-8605aff0ee6d.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 6738Y
Diaceutics PLC
08 September 2022
8 September 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Notice of Results and Presentations
Diaceutics PLC, (AIM: DXRX), a leading diagnostic commercialisation company which provides data, analytics and technology enabled services via its proprietary DXRX platform to the precision medicine market, confirms that it expects to announce its unaudited interim results for the six months ended 30 June 2022 on Tuesday, 27 September 2022.
Analyst Presentation
A webinar presentation for analysts will be held at 11 a.m. on Tuesday, 27 September 2022. Analysts wishing to attend should register their interest in advance with [email protected].
Investor Presentation
Peter Keeling, CEO, Nick Roberts, CFO, and Ryan Keeling, CIO, will provide a live presentation relating to the Company's results via the Investor Meet Company platform on Wednesday, 28 September 2022 at 1 p.m.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 a.m. the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Diaceutics via: https://www.investormeetcompany.com/diaceutics-plc/register-investor
Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.
Enquiries:
| Diaceutics PLC | |
| Nick Roberts, Chief Financial Officer | Via Alma PR |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Stewart Wallace | |
| Nick Adams | |
| Alma PR | Tel: +44(0)20 3405 0205 |
| Caroline Forde | [email protected] |
| Kieran Breheny | |
| Matthew Young |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCLRMFTMTBMBJT